A legal entity created on a voluntary basis and engaged in a certain business, company can operate in different market and counties. A company size is measured on the basis of its market value, sales, assets or profits. As a rule, companies are represented by the following types: be private, public, government, unlimited, foreign, producer, to name a few. Typical departments found in almost any company comprise but are not limited to production, customer services, marketing, human resources, finance, to name a few.
Exxon Mobil, JPMorgan Chase, Shell, Apple, Royal Dutch Shell and Toyota Motor are amidst the globe’s largest and most influential companies, with most of them active the world over.
This Catalogue’s research reports cover companies involved in various business activities, be it production, sales, marketing, etc. The reports contain information on companies’ activities, historical development, key executives, departments, product offerings. SWOT analyses, data on market share, marketing strategies, the most recent activities within the industry, acquisitions, strategic partnerships and alliances are included in the research reports.
Publications found:
193,061
Sort by:
Biocon - Market Perform, Result Helped By Unsustainable Other Income
US$ 140.00
BIOCON - Market Perform, Result helped by unsustainable other income We reiterate our Market Perform rating on Biocon despite the Q2 FY13 result being higher than our estimates. ... values Syngene at ~11x EV/EBITDA – 16% higher than Biocon’s market valuation. We keep our estimate unchanged. We now rollover our ...
November 2012
7 pages
Analysis of Glencore International
US$ 300.00
... and is expected to be completed shortly. Aruvian’s R’search presents Analysis of Glencore International. A complete and comprehensive analysis of Glencore International, includes an overview of the industry the company operates in and ...
November 2012
95 pages
Dr Reddy’S Lab - Market Perform, Great Result, Still Growth To Remain Modest
US$ 140.00
INDIA PHARMA Sub: DR REDDY’S LAB - Market Perform, Great Result, Still Growth to Remain Modest We reiterate our Market Perform rating on DRRD with an upward ... our estimate largely due to high growth in the US generics market business (17% Q-o-Q, constant currency). Other expenses remained lower sequentially ...
October 2012
8 pages
Gilead - Life Cycle Management For Hiv And Hcv Pipeline = Upside
US$ 140.00
... Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside Abstract 3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD ... , please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”. Report type – Deep ...
October 2012
7 pages
Alexion - Innovative Drugs For Orphan Diseases Focus = Stability!
US$ 140.00
Abstract Alexion (ALXN) products lack any near term competition ... products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying ... read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”
October 2012
5 pages
Ipca - Outperform, Momentum Continues
US$ 140.00
INDIA PHARMA Subject: IPCA – Outperform, Momentum Continues We reiterate our Outperform on Ipca post its Q2 ... forward sales growth will be driven by (1) continuing growth in the anti malarial tender business to WHO ... to US likely from FY13 and (3) continuing growth from India and other branded markets. While we ...
October 2012
7 pages
Lupin - Market Perform, Margin Worry On Base Business
US$ 140.00
INDIA PHARMA Subject: LUPIN - Market Perform, Margin worry on base business Lupin’s Q2FY13 result was largely inline with our estimates, however, ... R&D expense. Ex-branded US generic sales declined sequentially despite Combivir gaining market share in Q2 FY13. All these indicate pressure on the US base ...
October 2012
7 pages
Grifols, Ivig Opportunity In Ad - Dark Knight
US$ 140.00
... core business, bonus upside from positive data of IVIG in AD, and an attractive risk-reward profile, Grifols SA (GRF) is our preferred choice among three ... coverage initiation report released on 22nd Oct., 2012 on GRF titled, “GRIFOLS SA - IVIG Opportunity in AD - Dark Knight”.
October 2012
17 pages
